This systematic review included six primary studies involving 1059 patients with choroidal melanoma treated with PBT. The 2-, 3-, 5-, and 10-year OS rates were 97%, 92%, 73%, and 39%, respectively. The metastasis-free survival rates at 2, 3, and 5 years were 92%, 89%, and 76%, respectively, and the local control rates at 1, 3, 5, and 10 years were 98%, 92%, 94%, and 88%, respectively. The most common adverse reactions after PBT were glaucoma, optic neuropathy, and cataracts, with incidence rates ranging from 17.9 to 27%, 12.8-64%, and 29.6-39.8%, respectively. The authors suggested that their data showed an inferior 5-year OS with PBT compared to plaque brachytherapy where OS was reported 81.5 – 90%, however, the local control rate of PBT was superior to that of plaque which ranged from 59.0% to 98.0%.